Enzymatic Biofuel Cells for Self-Powered, Controlled Drug Release
Self-powered drug-delivery systems based on conductive polymers (CPs) that eliminate the need for external power sources are of significant interest for use in clinical applications. Osmium redox polymer-mediated glucose/O2 enzymatic biofuel cells (EBFCs) were prepared with an additional CP-drug layer on the cathode. On discharging the EBFCs in the presence of glucose and dioxygen, model drug compounds incorporated in the CP layer were rapidly released with negligible amounts released when the EBFCs were held at open circuit. Controlled and ex situ release of three model compounds, ibuprofen (IBU), fluorescein (FLU), and 4',6-diamidino-2-phenylindole (DAPI), was achieved with this self-powered drug-release system. DAPI released in situ in cell culture media was incorporated into retinal pigment epithelium (RPE) cells. This work demonstrates a proof-of-concept responsive drug-release system that may be used in implantable devices.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:142 |
|---|---|
| Enthalten in: |
Journal of the American Chemical Society - 142(2020), 26 vom: 01. Juli, Seite 11602-11609 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xiao, Xinxin [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.04.2021 Date Revised 15.04.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/jacs.0c05749 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31090417X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31090417X | ||
| 003 | DE-627 | ||
| 005 | 20231225141112.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/jacs.0c05749 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1036.xml |
| 035 | |a (DE-627)NLM31090417X | ||
| 035 | |a (NLM)32510936 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xiao, Xinxin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Enzymatic Biofuel Cells for Self-Powered, Controlled Drug Release |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2021 | ||
| 500 | |a Date Revised 15.04.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Self-powered drug-delivery systems based on conductive polymers (CPs) that eliminate the need for external power sources are of significant interest for use in clinical applications. Osmium redox polymer-mediated glucose/O2 enzymatic biofuel cells (EBFCs) were prepared with an additional CP-drug layer on the cathode. On discharging the EBFCs in the presence of glucose and dioxygen, model drug compounds incorporated in the CP layer were rapidly released with negligible amounts released when the EBFCs were held at open circuit. Controlled and ex situ release of three model compounds, ibuprofen (IBU), fluorescein (FLU), and 4',6-diamidino-2-phenylindole (DAPI), was achieved with this self-powered drug-release system. DAPI released in situ in cell culture media was incorporated into retinal pigment epithelium (RPE) cells. This work demonstrates a proof-of-concept responsive drug-release system that may be used in implantable devices | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Anions |2 NLM | |
| 650 | 7 | |a Indoles |2 NLM | |
| 650 | 7 | |a Polymers |2 NLM | |
| 650 | 7 | |a Osmium |2 NLM | |
| 650 | 7 | |a 2E7M255OPY |2 NLM | |
| 650 | 7 | |a DAPI |2 NLM | |
| 650 | 7 | |a 47165-04-8 |2 NLM | |
| 650 | 7 | |a Glucose Oxidase |2 NLM | |
| 650 | 7 | |a EC 1.1.3.4 |2 NLM | |
| 650 | 7 | |a Oxidoreductases Acting on CH-CH Group Donors |2 NLM | |
| 650 | 7 | |a EC 1.3.- |2 NLM | |
| 650 | 7 | |a bilirubin oxidase |2 NLM | |
| 650 | 7 | |a EC 1.3.3.5 |2 NLM | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 650 | 7 | |a Oxygen |2 NLM | |
| 650 | 7 | |a S88TT14065 |2 NLM | |
| 650 | 7 | |a Fluorescein |2 NLM | |
| 650 | 7 | |a TPY09G7XIR |2 NLM | |
| 650 | 7 | |a Ibuprofen |2 NLM | |
| 650 | 7 | |a WK2XYI10QM |2 NLM | |
| 700 | 1 | |a McGourty, Kieran Denis |e verfasserin |4 aut | |
| 700 | 1 | |a Magner, Edmond |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American Chemical Society |d 1945 |g 142(2020), 26 vom: 01. Juli, Seite 11602-11609 |w (DE-627)NLM00000569X |x 1520-5126 |7 nnns |
| 773 | 1 | 8 | |g volume:142 |g year:2020 |g number:26 |g day:01 |g month:07 |g pages:11602-11609 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/jacs.0c05749 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 142 |j 2020 |e 26 |b 01 |c 07 |h 11602-11609 | ||